Prior to treating children, adolescents, and adults with CNS stimulants, including Quillivant XR, assess each patient’s risk for abuse, misuse, and addiction. Assess for the presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). Assess the family history and clinically evaluate patients for motor or verbal tics or Tourette's syndrome. The recommended starting dose of Quillivant XR for patients 6 years and above is 20 mg once daily in the morning. The dose may be titrated weekly in increments of 10 mg to 20 mg. Daily doses above 60 mg have not been studied and are not recommended. If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug. If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.